China bribery scandal may affect pharma's emerging markets

10/15/2013 | Pharmalot

Several global pharmaceutical firms have acknowledged that the bribery scandal in China has slowed sales, but their chief concern is whether it will affect business in such emerging markets as Brazil, Russia and India, where growth had been slowing before the bribery issue arose. One-third of Sanofi's revenue comes from emerging markets, compared to approximately 26% for Roche, GlaxoSmithKline and Novartis.

View Full Article in:

Pharmalot

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY